Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2016-12-12 Regulatory Filings
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
ABIVAX S.A.: ExpreS2ion und ABIVAX geben Kooperation fur die Entwicklung des Prophylaxe- und Therapieprogramms ABX544 bekannt
Regulatory Filings Classification · 1% confidence The document is a press release dated December 12, 2016, announcing a cooperation agreement between ExpreS2ion and ABIVAX regarding the development of the ABX544 program (an Ebola prophylactic/therapeutic). It details the signing of a Service Agreement and a Term Sheet for a commercial license. This type of announcement, detailing strategic business development, partnerships, and initial financial/development terms, fits best under a general regulatory announcement or a specific corporate action announcement. Since it is not a full financial report (10-K, IR, ER), a management discussion (MDA), or a specific insider trade (DIRS), it falls under the category of a general regulatory announcement or news release. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a significant corporate news item that isn't covered by the more specific financial or governance codes, especially since it mentions being distributed via DGAP (a regulatory news service). However, since the content is a specific business development announcement, and not just a placeholder for a report, RNS is the best fit among the provided codes for a general corporate news release.
2016-12-12 German
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release dated December 12, 2016, announcing a collaboration agreement between ExpreS²ion and ABIVAX regarding the development of an Ebola treatment (ABX544). It details the terms of service and license agreements, provides background on Ebola and ABX544, includes management commentary, and lists contact information. This type of announcement, detailing a significant business development (collaboration/licensing deal) but not being a formal regulatory filing like a 10-K or a specific financial report (ER, IR), best fits the category for general corporate news or regulatory announcements. Since it is a formal press release announcing a strategic business development, it is most appropriately classified as a Regulatory Filing (RNS) as a general catch-all for significant, non-standardized corporate news, or potentially a Capital/Financing Update (CAP) if the deal involved significant upfront payments, but the text focuses on the collaboration structure rather than immediate financing. Given the context of corporate news dissemination, RNS is the most suitable general classification for this type of announcement that isn't explicitly an ER, IR, or DEF 14A.
2016-12-12 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release dated December 12, 2016, announcing a development collaboration and service agreement between ExpreS2ion and ABIVAX regarding the Ebola program ABX544. It details the terms of the agreement (Service Agreement and License Agreement term sheet) and provides background on Ebola and the product. This type of announcement, detailing a strategic partnership, financing/development agreement, or significant corporate event, is typically classified as a general Regulatory Filing (RNS) if it doesn't fit a more specific category like Capital/Financing Update (CAP) or M&A (TAR). Since this is a collaboration agreement and not a financing event, a management change, or a specific financial report, RNS is the most appropriate general regulatory announcement category. It is not a formal report (10-K, IR, ER, etc.) but an announcement of corporate activity.
2016-12-12 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document title is "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references articles from the French Commercial Code (Code de commerce) and the General Regulation of the AMF (Autorité des marchés financiers), which mandate the disclosure of the total number of shares and voting rights, typically on the 15th of each month or upon significant changes. This specific disclosure relates to the total share count and voting rights as of November 30, 2016. This type of regular statutory disclosure regarding share capital structure and voting power is best classified as a notification related to share capital changes or a general regulatory filing. Given the options, 'Share Issue/Capital Change' (SHA) is the most relevant category as it deals directly with the composition of the share capital and voting rights, even if it's a periodic update rather than a new issuance. It is not a dividend notice (DIV), director dealing (DIRS), or major shareholding notification (MRQ) which focus on ownership changes by specific parties or dividend payments. Since it is a direct disclosure of capital structure metrics, SHA is the most precise fit over the general RNS.
2016-12-09 French
ABIVAX prasentiert neue praklinische Daten, die den Einsatz von ABX464 zur funktionellen Heilung von HIV und als neuartige Therapie fur Entzundungskrankheiten unterstutzen, auf dem HIV DART Meeting
Regulatory Filings Classification · 1% confidence The document is a press release dated December 8, 2016, originating from ABIVAX, announcing scientific data presented at the 'HIV DART Meeting' regarding their drug candidate ABX464. It details preclinical findings supporting its use for HIV functional cure and inflammatory diseases, and announces a future Proof-of-Concept study for Inflammatory Bowel Disease (CED). The structure, use of 'DGAP-News', and focus on recent scientific/study results strongly indicate this is an announcement of results, not a comprehensive annual report (10-K), an interim report (IR), or a formal earnings release (ER) which typically focuses on standardized financial metrics. Since it is a specific announcement of study results and corporate news that doesn't fit the other specific categories (like DIV, CAP, MANG), it falls best under the general Regulatory Filings/News category, or potentially an Earnings Release if the context implied financial results, but here the focus is purely scientific/clinical data presentation. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news announcement of this nature that isn't a core financial filing or a transcript.
2016-12-08 German
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release dated December 8, 2016, announcing new preclinical data for the drug candidate ABX464 presented at a scientific conference (HIV DART Meeting). It details scientific findings (upregulation of IL-22, miR-124) and announces future plans (starting a clinical proof-of-concept study for IBD in 2017). This content is characteristic of an announcement regarding scientific progress or research updates, rather than a formal regulatory filing (like 10-K, IR, or ER). Since there is no specific category for 'Scientific Data Release' or 'Press Release', and it is not a formal financial report, management change, or shareholder vote result, the most appropriate general category for a non-standard, non-financial regulatory announcement is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous corporate announcements that don't fit elsewhere, although 'Investor Presentation' (IP) might be considered if it were a slide deck. Given the format is a news release detailing research updates, RNS is the best fit among the provided options for a general corporate update that isn't a core financial filing or management event.
2016-12-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.